Home / News / SHL Medical / Enabling large-volume/high-dose subcutaneous autoinjections with cartridge-based technologies
Articles and Editorials| February 09, 2023

Enabling large-volume/high-dose subcutaneous autoinjections with cartridge-based technologies

A banner image of SHL Medical’s February 2023 ONdrug Delivery magazine article by Senior Director of Market Intelligence Michael McGowan about the Maggie autoinjectors

In the latest issue of ONdrug Delivery magazine, Michael McGowan, Senior Director of Market Intelligence at SHL Medical, examines the emerging interest within the pharmaceutical industry for autoinjectors that are capable of delivering higher injection volumes into the subcutaneous space. 

 The article initially discusses how autoinjector products have been designed historically with pre-filled syringes as the primary container. In the context of large-volume, high-dose autoinjector combination product development,  the article then outlines some of the potential benefits of cartridge-based 3.0 mL and 5.0 mL autoinjectors as well as their suitability to address the needs of the biotech industry and patients in this evolving market segment. In May 2022, SHL Medical launched the Maggie 5.0 autoinjector.  Incorporating the market-proven Needle Isolation Technology (NIT®) cannula unit, the Maggie 5.0 is a two-step autoinjector that eliminates the need for users to manually attach the needle prior to injection. Moreover, NIT® is available in a range of gauges and lengths not readily available with prefilled syringes, allowing for full control and customization of the pre-attached cannula dimensions. 

 

Download the full article

 

Access the article here to learn more about SHL’s recently expanded drug delivery solutions for large-volume/high-dose drug delivery, now including the Maggie 5.0 autoinjector.

About SHL Medical

As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by our company purpose – Enabling Patients’ Independence – we offer patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. We also offer final assembly, labeling, and packaging solutions for our drug delivery systems.  ​

In response to the rising trend in home therapy, SHL has increased developmental work in the digital healthcare sector to help improve the drug delivery ecosystem. ​

Located across Switzerland, Taiwan, Sweden, and the US, our global team of experts collaborate seamlessly as one team in utilizing our comprehensive in-house manufacturing capabilities. Our solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into our designs and processes to contribute to a cleaner earth.​

For additional information, visit www.shl-medical.com

Media contact: info@shl-medical.com

Share:

Related News

SHL Medical October 2023 ONdrug Delivery magazine article banner
SHL Medical |Oct 2023

Strengthening a global manufacturing network through advanced simulation technologies

In the Pre-filled Syringes and Injection Devices Issue of ONdrug Delivery Magazine, published ahead of the 2023 PDA Universe of Pre-filled Syringes and Injection Devices Conference, SHL Medical’s Edwin Hendrawan, Yi-Chi Lu, and Christian Walter detail how simulation technologies have been crucial in continuously strengthening the company’s global manufacturing operations and expansion plans.

Read More